Fig. 5.
Evaluation of cross-protection conferred by PR8-amiR-93NP against infection with H3N2 influenza virus and pandemic 2009 H1N1 influenza virus. Mice (n=8) were vaccinated with 102 EID50 PR8-amiR-93NP and challenged with 104 PFU HK68 H3N2 influenza virus or 100 LD50 CA09 H1N1 pandemic influenza virus. (A) Mouse weight change and (B) survival rate for mice challenged with HK68 H3N2 influenza virus; (C) mouse weight change and (D) survival rate for mice challenged with CA09 H1N1 pandemic influenza virus. (**p<0.05).